Marinomed Biotech AG · VIE:MARI

Marinomed Biotech — Corporate Update (October 2020)

16 slides from Marinomed Biotech's corporate update, Oct 27, 2020

  1. Slide 1: The Marinosolv Technology Platform

    The Marinosolv Technology Platform Enables novel aqueous formulation of hardly soluble compounds Solve the un(dis)solvable

  2. Slide 2: Company highlights

    Company highlights Innovative biopharmaceutical company focused on respiratory, allergy and ophthalmic OTC and Rx therapies Established biopharmaceutical company with a global presence • Unique, asset-light business model with significant growth potential 1 • Significant pipeline with multiple, deri

  3. Slide 3: Marinosolv optimises local drug delivery

    Marinosolv® optimises local drug delivery Technology platform for novel aqueous formulations of virtually any drug An improved way of formulating poorly soluble compounds for sensitive tissues Faster onset of action Improvement of local activity Reduction of administered dose Better patient adherenc

  4. Slide 4: Marinosolv

    Marinosolv® Platform technology for formulation of insoluble locally applied drugs Increase of solubility of compounds due to Marinosolv® Shown in multiple experiments Compound fold-increase of solubility compared to water Steroid Budesonide > 10-fold Fluticasone propionate 50-100-fold Mometasone fu

  5. Slide 5: Marinosolv Platform Technology for Formulation of Pharmaceutical Ingredients Hardly Soluble in Water

    Marinosolv® Platform Technology for Formulation of Pharmaceutical Ingredients Hardly Soluble in Water A versatile delivery system that could improve bioavailability for potent compounds • Marinosolv® is a patent-protected technology platform enabling novel well tolerated aqueous solutions of relativ

  6. Slide 6: Marinosolv enhances bioavailability

    Marinosolv® enhances bioavailability Preclinical studies strongly suggest increased bioavailability in a variety of organs Increased permeability of fluorescently labelled dissolved estradiol compared to a suspension porcine nasal tissue culture Suspended particles Stable micelles Suspension Marinos

  7. Slide 7: Marinosolv portfolio overview

    Marinosolv® portfolio overview Budesolv finished clinical phase III and Tacrosolv ready for phase II 1 Nasal products • Budesolv 10µg nasal spray for allergic rhinitis 2 • Flutisolv nasal spray for allergic rhinitis 1 • Nasal formulation of macrolide immunosuppressant for non- steroid treatment of a

  8. Slide 8: Budesolv will be very competitive

    Budesolv will be very competitive Budesolv, a strong competitive edge in allergic rhinitis Rhinocort Aqua 64 g nasal spray Budesolv 10 g nasal spray • Budesolv 10 g nasal spray will have a (suspension of Budesonide, 64 g per (solution of Budesonide, 10 g per very strong competitive advantage do

  9. Slide 9: Steroids exemplified by Budesonide

    STEROIDS EXEMPLIFIED BY BUDESONIDE 9

  10. Slide 10: Efficacy of dissolved Budesonide versus suspensions in a murine lung inflammation model

    Efficacy of dissolved Budesonide versus suspensions in a murine lung inflammation model Strong decrease of TNF-alpha production in a murine inflammatory lung model A dose of 300 µg/ml dissolved Budesonide is more effective in reducing TNF-alpha release than the marketed product with 1.28 mg/ml suspe

  11. Slide 11: Budesolv demonstrates superiority of a Marinosolv enabled corticosteroid compared to marketed product

    Budesolv demonstrates superiority of a Marinosolv® enabled corticosteroid compared to marketed product Successful Phase III supports clinical efficacy and fast onset of action Primary endpoint of non-inferiority met Key secondary endpoint of fast onset met • Result to demonstrate a reduction of TNSS

  12. Slide 12: Immunosuppressants Tacrolimus

    IMMUNOSUPPRESSANTS TACROLIMUS 12

  13. Slide 13: Tacrosolv - optimised eye therapies

    Tacrosolv - optimised eye therapies Marinosolv®-enabled novel formulation of Tacrolimus Enabling Tacrolimus to reach its full potential… …for treating largely unmet medical needs • Macrolide immunosuppressants such as Tacrolimus • Allergic conjunctivitis is an inflammation and Cyclosporine A show ac

  14. Slide 14: Increased tissue concentration of Tacrolimus due to Marinosolv

    Increased tissue concentration of Tacrolimus due to Marinosolv® Tacrolimus concentration in porcine cornea (ex-vivo) 12 11 10 9 8 FK506 [µg/g tissue] 7 6 5 4 3 2 1 0 300 µg/ml Tacrosolv 500 µg/ml Tacrosolv 700 µg/ml Tacrosolv 1000 µg/ml Talymus Different Marinosolv enabled Tacrolimus formulations (T

  15. Slide 15: Increased tissue concentration of Tacrolimus due to Marinosolv

    Increased tissue concentration of Tacrolimus due to Marinosolv® Tacrolimus concentration in porcine cornea (in-vivo) Tacrolimus concentration in porcine pigmented layer (in-vivo) 16 400 14 350 12 300 FK506 [ng/g tissue] FK506 [µg/g tissue] 10 250 8 200 6 150 4 100 2 50 0 0 3.5 µg / kg BW / day 7.0 µ

  16. Slide 16: Solve the un(dis)solvable Contact BD&L

    Solve the un(dis)solvable Contact BD&L bd@marinomed.com www.marinomed.com

Marinomed Biotech — Corporate Update (October 2020) on 6ix